Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Linical CoTSE:2183 40 3-1 Month Momentum % is -7.17% as of Aug. 28, 2026. GuruFocus rates TSE:2183 with a GF Score™ of 40/100 and a GF Value™ of 円334.42 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,389 Biotechnology companies, Linical Co ranks better than 55.65% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-28), Linical Co's 3-1 Month Momentum % is -7.17%.
The industry rank for Linical Co's 3-1 Month Momentum % or its related term are showing as below:
TSE:2183's 3-1 Month Momentum % is ranked better than 55.65% of 1389
companies
in the Biotechnology industry
Industry Median: -8
vs TSE:2183: -7.17
Linical Co (TSE:2183) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Linical Co 3-1 Month Momentum % Related Terms
TSE:2183 vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Linical Co's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Linical Co 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Linical Co's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Linical Co's 3-1 Month Momentum % falls into.
Linical Co (TSE:2183) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Linical Co (TSE:2183) has a 3-1 Month Momentum % of -7.17% as of Aug. 28, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Linical Co and its competitors. According to the industry distribution chart, Linical Co ranks #616 out of 1389 companies in the Biotechnology industry, placing it in the top 44.3%.
Is Linical Co's 3-1 Month Momentum % too high?
Linical Co's current 3-1 Month Momentum % is -7.17%. Based on the distribution chart, Linical Co ranks #616 out of 1389 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Linical Co has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Linical Co's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Linical Co ranks #616 out of 1389 companies for 3-1 Month Momentum %. This puts Linical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Linical Co and its competitors. Linical Co's current 3-1 Month Momentum % is -7.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Linical Co stock overvalued right now?
Based on GuruFocus' analysis, Linical Co (TSE:2183) is currently considered Possible Value Trap. The stock's GF Value™ is 円334.42, compared to a current price of 円207.00 — trading 38.1% below its estimated fair value. The current 3-1 Month Momentum % is -7.17%. Linical Co's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Linical Co (TSE:2183), the current 3-1 Month Momentum % is -7.17% as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Linical Co (TSE:2183) Overvalued in 2026?
Based on GuruFocus' analysis, Linical Co stock appears to be undervalued.
The current stock price of 円207.00 is trading 38.1% below its estimated GF Value™ of 円334.42.
GuruFocus considers Linical Co to be Possible Value Trap.
Key valuation signals for TSE:2183:
3-1 Month Momentum %: -7.17%
GF Value™: 円334.42 vs. price of 円207.00 (38.1% below fair value)
No single metric tells the full story. See the TSE:2183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2183 has been successfully added to your 
